[go: up one dir, main page]

IT1206311B - Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso. - Google Patents

Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso.

Info

Publication number
IT1206311B
IT1206311B IT8223872A IT2387282A IT1206311B IT 1206311 B IT1206311 B IT 1206311B IT 8223872 A IT8223872 A IT 8223872A IT 2387282 A IT2387282 A IT 2387282A IT 1206311 B IT1206311 B IT 1206311B
Authority
IT
Italy
Prior art keywords
oligonucleotide
organism
production
methods
same
Prior art date
Application number
IT8223872A
Other languages
English (en)
Other versions
IT8223872A0 (it
Inventor
Richard H Tullis
Original Assignee
Molecular Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23218662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1206311(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Molecular Biosystems Inc filed Critical Molecular Biosystems Inc
Publication of IT8223872A0 publication Critical patent/IT8223872A0/it
Application granted granted Critical
Publication of IT1206311B publication Critical patent/IT1206311B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IT8223872A 1981-10-23 1982-10-22 Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso. IT1206311B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31412481A 1981-10-23 1981-10-23

Publications (2)

Publication Number Publication Date
IT8223872A0 IT8223872A0 (it) 1982-10-22
IT1206311B true IT1206311B (it) 1989-04-14

Family

ID=23218662

Family Applications (1)

Application Number Title Priority Date Filing Date
IT8223872A IT1206311B (it) 1981-10-23 1982-10-22 Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso.

Country Status (12)

Country Link
US (2) US7285537B1 (it)
EP (1) EP0092574B1 (it)
JP (2) JP2547714B2 (it)
AT (1) ATE75483T1 (it)
AU (1) AU568067B2 (it)
CA (1) CA1208147A (it)
DE (1) DE3280400D1 (it)
DK (1) DK288183A (it)
IE (1) IE58009B1 (it)
IL (1) IL67053A (it)
IT (1) IT1206311B (it)
WO (1) WO1983001451A1 (it)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983001451A1 (en) * 1981-10-23 1983-04-28 Molecular Biosystems Inc Oligonucleotide therapeutic agent and methods of making same
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en) * 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5272065A (en) * 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
EP0477994B1 (en) * 1985-03-21 2001-06-13 Johnston, Stephen, Ph.D. Parasite-derived resistance
US5580716A (en) * 1985-03-21 1996-12-03 Stephen A. Johnston Parasite-derived resistance
US4959463A (en) * 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
EP0252940A4 (en) * 1985-12-05 1989-07-27 Hutchinson Fred Cancer Res Anti-sense rna for treatment of retroviral disease states.
US5453566A (en) * 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5637573A (en) * 1986-05-23 1997-06-10 Agrawal; Sudhir Influenza virus replication inhibiting oligonucleotide analogues and their pharmaceutical compositions
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
AU613989B2 (en) * 1987-11-24 1991-08-15 Gen-Probe Incorporated Means and method for enhancing nucleic acid hybridization
WO1989005358A1 (en) * 1987-11-30 1989-06-15 University Of Iowa Research Foundation Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
AU4180889A (en) * 1988-07-05 1990-02-05 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
FR2686882B1 (fr) * 1992-02-05 1994-05-06 Centre Nat Rech Scient Oligothionucleotides.
FR2687679B1 (fr) * 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
US5633360A (en) * 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
AU6497694A (en) * 1993-04-02 1994-10-24 Ribogene, Inc. Method for selective inactivation of viral replication
US6824976B1 (en) 1993-04-02 2004-11-30 Rigel Pharmaceuticals, Inc. Method for selective inactivation of viral replication
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US7262173B2 (en) * 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
CA2326823A1 (en) 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
US6887464B1 (en) 1999-02-02 2005-05-03 Biocache Pharmaceuticals, Inc. Advanced antigen presentation platform
NZ513935A (en) 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
DE60131430T2 (de) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
SI1296714T1 (sl) 2000-06-22 2010-01-29 S For Entpr University Of Iowa Kombinacija CpG-ja in protiteles, usmerjenih proti CD19, CD20, CD22 ali CD40 za zdravljenje ali preprečevanje raka
EP1350262B8 (en) 2000-12-08 2008-08-13 Coley Pharmaceuticals GmbH Cpg-like nucleic acids and methods of use thereof
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
WO2003015711A2 (en) 2001-08-17 2003-02-27 Coley Pharmaceutical Group, Inc. Combination motif immune stimulatory oligonucleotides with improved activity
US7514414B2 (en) 2001-09-24 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Suppressors of CpG oligonucleotides and methods of use
US7514415B2 (en) 2002-08-01 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
AU2002346960A1 (en) 2001-10-06 2003-04-22 Merial Limited Methods and compositions for promoting growth and innate immunity in young animals
WO2003054161A2 (en) 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
ES2734652T3 (es) 2002-04-04 2019-12-11 Zoetis Belgium S A Oligorribonucleótidos inmunoestimulantes que contienen G y U
US20050153297A1 (en) * 2002-05-29 2005-07-14 Ateeq Ahmad Method for determining oligonucleotide concentration
US7704965B2 (en) * 2002-06-26 2010-04-27 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US20050059025A1 (en) * 2002-10-07 2005-03-17 Five Giralda Farms Compositions, organisms and methodologies employing a novel human kinase
US8043622B2 (en) 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
EP1549749A4 (en) * 2002-10-10 2007-08-22 Wyeth Corp COMPOSITIONS, ORGANISMS AND METHODS USING A NEW HUMAN KINASE
CA2501752A1 (en) * 2002-10-10 2004-04-22 Wyeth Compositions, organisms and methodologies employing a novel human kinase
WO2004036221A2 (en) * 2002-10-18 2004-04-29 Wyeth Compositions and methods for diagnosing and treating autoimmune disease
CA2503491A1 (en) * 2002-10-24 2004-05-06 Wyeth Calcineurin-like human phosphoesterase
BR0315810A (pt) 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c
JP2006514554A (ja) * 2002-11-21 2006-05-11 ワイス 腎細胞癌および他の固形腫瘍の診断法
AU2003290664A1 (en) 2002-11-27 2004-06-23 Wei Liu Compositions, organisms and methodologies employing a novel human kinase
US7803365B2 (en) * 2002-12-02 2010-09-28 Biovec, Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
US9388427B2 (en) * 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
EP1581812B1 (en) * 2003-01-06 2008-07-16 Wyeth Compositions and methods for diagnosing and treating colon cancers
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
US20050106124A1 (en) * 2003-02-25 2005-05-19 Sehgal Lakshman R. Therapeutic applications of thrombomodulin gene via viral and non-viral vectors
US20040191818A1 (en) * 2003-02-26 2004-09-30 O'toole Margot Mary Compositions and methods for diagnosing and treating autoimmune diseases
US20040234517A1 (en) * 2003-03-04 2004-11-25 Wyeth Compositions and methods for diagnosing and treating asthma or other allergic or inflammatory diseases
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
WO2005001092A2 (en) * 2003-05-20 2005-01-06 Wyeth Compositions and methods for diagnosing and treating cancers
WO2005020902A2 (en) * 2003-08-21 2005-03-10 Cytokine Pharmasciences, Inc. Compositions and methods for treating and diagnosing irritable bowel syndrome
EP1663316A2 (en) 2003-09-25 2006-06-07 Coley Pharmaceutical Group, Inc. Nucleic acid lipophilic conjugates
US20050244505A1 (en) * 2003-12-11 2005-11-03 Higbee Russell G Immunotherapy compositions, method of making and method of use thereof
EP2248895B8 (en) 2003-12-19 2016-09-21 Autotelic LLC Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
WO2005097993A2 (en) 2004-02-19 2005-10-20 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
EP1568383A3 (en) 2004-02-27 2005-11-16 Antisense Pharma GmbH Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005115359A2 (en) 2004-05-06 2005-12-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
JP2008506789A (ja) 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
CN101014245A (zh) 2004-08-03 2007-08-08 比奥根艾迪克Ma公司 神经元功能中的taj
KR100721928B1 (ko) 2004-11-05 2007-05-28 주식회사 바이오씨에스 ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
US7935811B2 (en) 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
US7923206B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Method of determining a cellular response to a biological agent
US7939490B2 (en) * 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
US9809824B2 (en) 2004-12-13 2017-11-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
FR2881143B1 (fr) 2005-01-27 2010-12-17 Librophyt Systeme de production de terpenoides dans les plantes
US20100130425A1 (en) 2005-09-09 2010-05-27 Oregon Health & Science University Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
PT1981902E (pt) 2006-01-27 2015-11-02 Biogen Ma Inc Antagonistas dos recetores nogo
CA2642152C (en) 2006-02-15 2016-11-01 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
AU2007299705B2 (en) 2006-09-22 2012-09-06 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
AU2007353317B2 (en) * 2006-11-15 2012-09-06 Eli Lilly And Company Methods and compositions for treating influenza
PL2170353T3 (pl) 2007-05-18 2015-10-30 Adiutide Pharmaceuticals Gmbh Modyfikowane fosforanami analogi oligonukleotydów wykazujące aktywność immunostymulującą
RU2010112771A (ru) 2007-10-09 2011-11-20 Коули Фармасьютикал ГмбХ (DE) Иммуностимулирующие аналоги олигонуклеотидов, содержащие модифицированные сахарные группировки
AU2008326187B2 (en) 2007-11-06 2014-12-04 Adiutide Pharmaceuticals Gmbh Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
US7845686B2 (en) * 2007-12-17 2010-12-07 S & B Technical Products, Inc. Restrained pipe joining system for plastic pipe
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
US8222225B2 (en) 2008-05-21 2012-07-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating pneumoconiosis with oligodeoxynucleotides
PE20110891A1 (es) 2008-12-09 2011-12-23 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
PE20110998A1 (es) 2008-12-09 2012-02-10 Coley Pharm Group Inc Oligonucleotidos inmunoestimuladores
US8552165B2 (en) 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
RU2536248C2 (ru) 2009-04-30 2014-12-20 Коули Фармасьютикал Груп, Инк. Пневмококковая вакцина и ее применения
RU2012107535A (ru) 2009-07-30 2013-09-10 Антисенс Фарма Гмбх КОМБИНАЦИЯ ХИМИОТЕРАПЕВТИЧЕСКОГО СРЕДСТВА И ИНГИБИТОРА СИСТЕМЫ TGF-β
KR20130127547A (ko) 2009-07-30 2013-11-22 화이자 백신스 엘엘씨 항원성 타우 펩타이드 및 이의 용도
MX2012002639A (es) 2009-09-03 2012-03-14 Pfizer Vaccines Llc Vacuna de pcsk9.
WO2011109422A2 (en) 2010-03-02 2011-09-09 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of cancer
JP2011251963A (ja) 2010-05-28 2011-12-15 Coley Pharmaceutical Group Inc 抗原および免疫調節ワクチンおよびコレステロール、ならびにその使用
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US9328346B2 (en) 2010-11-12 2016-05-03 The General Hospital Corporation Polycomb-associated non-coding RNAs
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
CN103732529B (zh) 2011-07-01 2017-07-04 哈佛学院院长等 用于形成具有预定形状的纳米颗粒的方法
CA2848753C (en) 2011-09-14 2022-07-26 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
EP2830991A1 (en) 2012-03-26 2015-02-04 President and Fellows of Harvard College Lipid-coated nucleic acid nanostructures of defined shape
CA2871490C (en) 2012-04-27 2022-10-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelerate wound healing
KR102125658B1 (ko) 2012-05-04 2020-06-22 화이자 인코포레이티드 전립선 관련된 항원 및 백신 기재 면역치료 요법
EA201492122A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии utrn
EP2850188A4 (en) 2012-05-16 2016-01-20 Rana Therapeutics Inc COMPOSITIONS AND METHOD FOR MODULATING THE EXPRESSION OF THE HEMOGLOBIN GENE FAMILIES
US10059941B2 (en) 2012-05-16 2018-08-28 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
US10174323B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating ATP2A2 expression
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
AU2013315225B2 (en) 2012-09-14 2018-11-08 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds
WO2014201245A1 (en) 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
WO2015023941A1 (en) 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Oligonucleotides targeting euchromatin regions of genes
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
CN106661616A (zh) 2014-04-23 2017-05-10 儿童医学中心公司 使用核酸卡尺的高通量结构测定
CA2966044A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
EP3240801B1 (en) 2014-12-31 2021-01-20 Checkmate Pharmaceuticals, Inc. Combination tumor immunotherapy
US10758558B2 (en) 2015-02-13 2020-09-01 Translate Bio Ma, Inc. Hybrid oligonucleotides and uses thereof
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
WO2016183371A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for the treatment or prevention of ischemic tissue damage
WO2016183370A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Synthetic immunosuppressive oligodeoxynucleotides reduce ischemic tissue damage
WO2017192874A1 (en) 2016-05-04 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Albumin-binding immunomodulatory compositions and methods of use thereof
WO2019113457A1 (en) 2017-12-07 2019-06-13 Massachusetts Institute Of Technology Single cell analyses
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
EP3775218A1 (en) 2018-04-09 2021-02-17 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
US20230241196A1 (en) 2020-01-27 2023-08-03 Oregon State University Gonorrhea subunit vaccine
JP2025541207A (ja) 2022-12-13 2025-12-18 ファイザー・インク クロストリディオイデス（クロストリジウム）・ディフィシル（ｃｌｏｓｔｒｉｄｉｏｉｄｅｓ（ｃｌｏｓｔｒｉｄｉｕｍ）ｄｉｆｆｉｃｉｌｅ）に対する免疫応答を誘発するための免疫原性組成物および方法
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025238502A1 (en) 2024-05-14 2025-11-20 Pfizer Inc. Aluminum adjuvant nanoparticles, methods of manufacture, and uses thereof
WO2025257712A1 (en) 2024-06-12 2025-12-18 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4321365A (en) * 1977-10-19 1982-03-23 Research Corporation Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules
GB2068971B (en) * 1980-01-30 1983-06-08 Searle & Co Recombinant dna techniques
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
WO1983001451A1 (en) * 1981-10-23 1983-04-28 Molecular Biosystems Inc Oligonucleotide therapeutic agent and methods of making same

Also Published As

Publication number Publication date
JPS58501771A (ja) 1983-10-20
DE3280400D1 (de) 1992-06-04
JP2547714B2 (ja) 1996-10-23
DK288183D0 (da) 1983-06-22
IT8223872A0 (it) 1982-10-22
WO1983001451A1 (en) 1983-04-28
IE822547L (en) 1983-04-23
US5919619A (en) 1999-07-06
IE58009B1 (en) 1993-06-16
US7285537B1 (en) 2007-10-23
ATE75483T1 (de) 1992-05-15
JPH08294393A (ja) 1996-11-12
EP0092574A1 (en) 1983-11-02
CA1208147A (en) 1986-07-22
IL67053A (en) 1997-07-13
EP0092574B1 (en) 1992-04-29
EP0092574A4 (en) 1984-02-09
AU9124382A (en) 1983-05-05
DK288183A (da) 1983-06-22
AU568067B2 (en) 1987-12-17

Similar Documents

Publication Publication Date Title
IT1206311B (it) Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso.
FR2681786B1 (it)
IT8119760A0 (it) Polipeptide prodotto microbiologicamente con la sequenza di aminoacidi dell'interferone umano, dna e plasmidi che codificano per questa sequenza, microorganismi che contengono queste informazioni genetiche e processo per la loro preparazione.
EP0168214A3 (en) Tumor necrosis factor, methods for its preparation, compositions containing it, dna encoding it and assay method using such dna
ES8705521A1 (es) Un metodo de producir un polipetido similar a factor de necrosis de tumores (tnf) de mamiferos.
MD430C2 (ro) Procedeu de obţinere a interferonelor leucocitare umane
DE69333346D1 (de) Neuartiges p- selectin ligandenprotein
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
NZ234453A (en) Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
IL75963A (en) Omega interferon polypeptides of type 1,n-glycosylated derivatives thereof with omega interferon activity,polynucleotide sequences encoding the omega interferon polypeptides,methods for the preparation of the polypeptides and pharmaceutical compositions containing them
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
EP0002322A3 (en) Improved triester process for the synthesis of oligonucleotides
ZA965586B (en) Coccidiosis poultry vaccine
ES2013500A6 (es) Metodo para producir una variante de secuencioa de aminoacidos de un activador de plasmionogeno.
EP0315118A3 (en) Dna coding for endothelin and use thereof
AU3172095A (en) Coccidiosis poultry vaccine
IT8119759A0 (it) Umano, dna e plasmidi che polipeptide prodotto codificano per questa sequenza, microbiologicamente con la sequenza microorganismi che contengono di aminoacidi dell'interferone queste informazioni genetiche e processo per la loro preparazione.
DE69730967D1 (en) Human dnase ii
IT8821123A0 (it) Clonaggio del gene che codifica l'enzima isoamilasi e suo impiego per la produzione di detto enzima o suoi analoghi.
IT8821282A0 (it) Clonaggio del gene che codifica l'enzima isoamilasi e suo impiego per la produzione di detto enzima o suoi analoghi.

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971029